Meeting discusses possible export of coronavirus vaccines: Report

A multi-ministerial meeting on Monday discussed various aspects of India's possible export of COVID-19 vaccines in view of requests from an increasing number of countries to procure the vaccines

vaccine
Press Trust of India New Delhi
2 min read Last Updated : Jan 19 2021 | 1:52 AM IST

A multi-ministerial meeting on Monday discussed various aspects of India's possible export of COVID-19 vaccines in view of requests from an increasing number of countries to procure the vaccines, people familiar with the development said.

The issue was discussed extensively at the virtual meeting attended by representatives from various ministries and agencies, including the Department of Pharmaceuticals and the Ministry of External Affairs (MEA), they said.

They said the ministries of health, commerce, external affairs and the Department of Pharmaceuticals are among the key stakeholders involved in the possible export of the vaccines.

India has already rolled out a massive coronavirus vaccination drive under which two vaccines, Covishield and Covaxin, are being administered to frontline health workers across the country.

While Oxford-AstraZeneca's Covishield is being manufactured by the Serum Institute of India, Covaxin is being produced by Bharat Biotech.

Several countries have approached India for the procurement of the vaccines. It is learnt that countries in India's neighbourhood are likely to get the supplies first.

On Thursday, MEA Spokesperson Anurag Srivastava said the government is assessing the production schedules and availability of the COVID-19 vaccines, and any decision on their supply to other countries "may take some time".

"In so far as requests from countries for vaccines from India, you would recall that Prime Minister (Narendra Modi) has already stated that India's vaccine production and delivery capacity would be used for the benefit of all humanity in fighting this crisis," he had said at a media briefing.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus Vaccine

First Published: Jan 19 2021 | 1:47 AM IST

Next Story